Clinical Trial Update: A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate adverse events and pharmacokinetics of intravenously delivered pivekimab sunirine in pediatric patients with relapsed or refractory ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Pivekimab Sunirine (IMGN632)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: NOT_YET_RECRUITING